Global Medical Nutritionals, Consumer Healthcare, Sanofi, Paris, France.
Clinical Pharmacology Center, INSERM CIC 1405, University Hospital Clermont-Ferrand, France.
Magnes Res. 2020 Aug 1;33(3):45-57. doi: 10.1684/mrh.2020.0468.
Primary findings from a recent study reported that magnesium supplementation significantly reduced stress in severely stressed subjects with low magnesemia, and additional vitamin B6 enhanced this effect. The mechanism by which combining magnesium and vitamin B6 leads to reduced stress in these subjects remains to be elucidated. This secondary analysis investigated the impact of magnesium and vitamin B6 supplementation and perceived stress on erythrocyte magnesium levels, as a marker of body magnesium status. This was a secondary analysis from an 8-week randomized controlled trial comparing oral magnesium (300 mg) and magnesium-vitamin B6 (300 mg + 30 mg) supplementation. Stress level and erythrocyte magnesium level at baseline, and change in erythrocyte magnesium and serum vitamin B6 levels at weeks 4 and 8, were analyzed. Overall, 264 subjects were randomized to treatment and had evaluable Depression Anxiety Stress Scale scores (132 in each treatment arm). At baseline, stress scores, and mean serum magnesium, erythrocyte magnesium, and serum vitamin B6 concentrations were similar between arms. Although not significant between groups, a significant increase over time in erythrocyte magnesium levels was observed in the subgroup of subjects with low baseline erythrocyte magnesium levels (<1.6 mmol/L) following treatment with magnesium and magnesium-vitamin B6 (week 4:0.21 mmol/L [95% confidence interval (CI), 0.10 to 0.31], p = 0.0003; and 0.13 mmol/L [95% CI, 0.02 to 0.23], p = 0.0233, respectively). Change from baseline in circulating vitamin B6 levels at weeks 4 and 8 in the magnesium-vitamin B6 supplemented group (314.96 nmol/L [95%CI, 294.61 to 335.31]) was significantly different (p < 0.0001) compared with the magnesium supplemented group (-0.39 nmol/L [95% CI, -20.73 to 19.94]). Magnesium alone and magnesium-vitamin B6 provided statistically significant increases in erythrocyte magnesium in subjects with low magnesium status (<1.6mmol/L). Vitamin B6 supplementation did not further increase magnesium levels.
最近的一项研究的主要发现表明,镁补充剂可显著降低低镁血症严重应激患者的应激水平,额外补充维生素 B6 可增强这种效果。联合使用镁和维生素 B6 可降低这些患者的应激的机制仍有待阐明。这项二次分析调查了镁和维生素 B6 补充剂和感知应激对红细胞镁水平的影响,红细胞镁水平作为体内镁状态的标志物。这是一项为期 8 周的随机对照试验的二次分析,该试验比较了口服镁(300mg)和镁-维生素 B6(300mg+30mg)补充剂的效果。分析了基线时的应激水平和红细胞镁水平,以及第 4 周和第 8 周时红细胞镁和血清维生素 B6 水平的变化。总体而言,264 名患者被随机分配到治疗组,并可评估抑郁焦虑应激量表评分(每组 132 名)。在基线时,两组的应激评分以及平均血清镁、红细胞镁和血清维生素 B6 浓度相似。尽管组间无统计学差异,但在基线红细胞镁水平较低(<1.6mmol/L)的亚组中,接受镁和镁-维生素 B6 治疗后,红细胞镁水平随着时间的推移呈显著升高(第 4 周:0.21mmol/L[95%置信区间(CI),0.10 至 0.31],p=0.0003;第 0.13mmol/L[95%CI,0.02 至 0.23],p=0.0233)。第 4 周和第 8 周时,镁-维生素 B6 补充组循环维生素 B6 水平的变化(314.96nmol/L[95%CI,294.61 至 335.31])与镁补充组(-0.39nmol/L[95%CI,-20.73 至 19.94])有显著差异(p<0.0001)。镁单独和镁-维生素 B6 可使低镁血症患者(<1.6mmol/L)的红细胞镁水平显著升高。维生素 B6 补充剂并不能进一步增加镁水平。